Menotropins

Jump to: navigation, search
Menotropins
Clinical data
Trade namesRepronex
MedlinePlusa601002
ATC code
Identifiers
CAS Number
ChemSpider
UNII
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Menotropins

Articles

Most recent articles on Menotropins

Most cited articles on Menotropins

Review articles on Menotropins

Articles on Menotropins in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Menotropins

Images of Menotropins

Photos of Menotropins

Podcasts & MP3s on Menotropins

Videos on Menotropins

Evidence Based Medicine

Cochrane Collaboration on Menotropins

Bandolier on Menotropins

TRIP on Menotropins

Clinical Trials

Ongoing Trials on Menotropins at Clinical Trials.gov

Trial results on Menotropins

Clinical Trials on Menotropins at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Menotropins

NICE Guidance on Menotropins

NHS PRODIGY Guidance

FDA on Menotropins

CDC on Menotropins

Books

Books on Menotropins

News

Menotropins in the news

Be alerted to news on Menotropins

News trends on Menotropins

Commentary

Blogs on Menotropins

Definitions

Definitions of Menotropins

Patient Resources / Community

Patient resources on Menotropins

Discussion groups on Menotropins

Patient Handouts on Menotropins

Directions to Hospitals Treating Menotropins

Risk calculators and risk factors for Menotropins

Healthcare Provider Resources

Symptoms of Menotropins

Causes & Risk Factors for Menotropins

Diagnostic studies for Menotropins

Treatment of Menotropins

Continuing Medical Education (CME)

CME Programs on Menotropins

International

Menotropins en Espanol

Menotropins en Francais

Business

Menotropins in the Marketplace

Patents on Menotropins

Experimental / Informatics

List of terms related to Menotropins

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Menotropin (also called human menopausal gonadotropin or hMG) is a hormonally active medication for the treatment of fertility disturbances. Frequently the plural is used as the medication is a mixture of gonadotropins. Menotropins are extracted from the urine of postmenopausal women.

Description and usage

Urine of postmenopausal women reflects the hypergonadotropic state of menopause -levels of follicle stimulating hormone (FSH) and luteinizing hormone (LH) are high - and contain a mixture of these gonadotropins. Other protein substances may be present, including small amounts of human chorionic gonadotropin (hCG). In 1949 Piero Donini found a relatively simple method to extract gonadotropins from urine of postmenopausal women. Menotropins were successfully introduced into clinical use by Bruno Lunenfeld in 1961 While earlier menotropin medications contained FSH and LH at a 1:1 ratio, the recognition that it is FSH that is critical for follicle stimulation has led to development of newer preparations that contain a much higher FSH/LH ratio, Fertinex being an example. Menotropin preparations are designed for use in selected women where they stimulate the ovaries to mature follicles, thus making them more fertile. They are administered by typically daily injection, intramuscularly or subcutaneously, for about ten days under close supervision to adjust dose and duration of therapy. They can also be used in hypogonadal men to stimulate sperm production.

Human urinary-derived menotropin preparations are exposed to the theoretical risk of infection from menopausal donors of urine. Nevertheless, the failure to irrefutably demonstrate infectivity following intracerebral inoculation with urine from transmissible spongiform encephalopathy(TSE)-infected hosts suggests that the risk associated with products derived from urine is merely theoretical

Recombinant gonadotropins have to a large degree replaced hMG in fertility treatments. The recombinant process allows for the production of pure FSH or LH not "contaminated" by other proteins that may be present after urinary extraction. While some head-on studies seem not to suggest that "pure FSH" gives better results than hMG., others claim that recombinant FSH is more efficient and reduces costs.A Cochrane Collaboration analysis did not reveal major differences in clinical outcomes when comparing urinary versus recombinant FSH.

The Practice Committee of the American Society for Reproductive Medicine reported:“Compared with earlier crude animal extracts, modern highly purified urinary and recombinant gonadotropin products have clearly superior quality, specific activity, and performance. There are no confirmed differences in safety, purity, or clinical efficacy among the various available urinary or recombinant gonadotropin products.”

List of hMG preparations

A number of drug companies have and had marketed hMG preparations that include:

  • Humegon (Organon),
  • Menopur (Ferring Pharmaceuticals), 75 IU FSH and 75 IU LH activity
  • Menogon,
  • Metrodin (Serono),
highly purified urinary FSH
  • Repronex (Ferring Pharmaceuticals), 75 IU FSH and 75 IU LH
  • Pergonal (Serono),
Pergonal was the major hMG prior to the arrival of recombinant gonadotropins containing 75 IU FSH and 75 IU LH. The first successful in-vitro fertilization in 1978 was achieved after follicle stimulation with the use of Pergonal
  • HMG Massone, 75 IU FSH and 75 IU LH

See also

References


Linked-in.jpg